{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:59:45Z","timestamp":1780693185086,"version":"3.54.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Current norepinephrine transporter (NET) tracers used for cardiac sympathetic imaging and oncology are limited by radiosynthesis complexity, suboptimal image quality, or operational constraints. [\n                      <jats:sup>18<\/jats:sup>\n                      F]fluproxadine (formerly [\n                      <jats:sup>18<\/jats:sup>\n                      F]AF78) was developed to address these limitations by providing high NET affinity, favorable biodistribution, and an operationally straightforward radiosynthesis. We therefore conducted the first-in-human evaluation of this new class of [\n                      <jats:sup>18<\/jats:sup>\n                      F] labeled NET PET tracer to assess its safety, biodistribution, radiation dosimetry, and imaging characteristics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      In a prospective study, 4 healthy adult volunteers received [\n                      <jats:sup>18<\/jats:sup>\n                      F]fluproxadine (101.8\u2013204.0 MBq). Dynamic whole-body PET\/CT acquisitions were obtained 10 times from 1 to 232 minutes postinjection, and vital signs, laboratory tests, and adverse events were monitored. Time-activity curves were generated for major organs, including myocardium from the whole-body scans, and organ-absorbed doses and effective dose were estimated using OLINDA\/EXM v2.0 from time-integrated activities. Myocardial uptake and target-to-background behavior were assessed using semiquantitative methods. Radiosynthesis performance and key operational steps were documented to assess practical scalability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Radiosynthesis of [\n                      <jats:sup>18<\/jats:sup>\n                      F]fluproxadine was operationally straightforward with encouraging yields and fewer specialized steps than some legacy tracers. Imaging was completed without serious adverse events. Biodistribution showed predominant renal clearance; biliary excretion was not observed within the imaging window. Highest organ doses were to the urinary bladder wall and kidneys, with additional uptake in liver, thyroid, salivary glands, and myocardium. The effective dose was 21.6\u00b11.5 \u00b5Sv\/MBq. Myocardial uptake was clearly visualized on whole-body images with favorable target-to-background characteristics at delayed time points, consistent with NET biology and supporting practical cardiac imaging windows.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]fluproxadine demonstrated clear myocardial uptake, acceptable radiation dosimetry comparable to typical\n                      <jats:sup>18<\/jats:sup>\n                      F PET agents, and an early safety profile without serious adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006504","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:00:08Z","timestamp":1780689608000},"page":"555-564","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["First-In-Human Evaluation of [18F]Fluproxadine for Norepinephrine Transporter PET"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0955-4272","authenticated-orcid":false,"given":"Tomohiko","family":"Yamane","sequence":"first","affiliation":[{"name":"Department of Molecular Imaging Research, Kobe City Medical Center General Hospital, Kobe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Iimori","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging Research, Kobe City Medical Center General Hospital, Kobe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Akamatsu","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging Research, Kobe City Medical Center General Hospital, Kobe"},{"name":"National Institutes for Quantum Science and Technology (QST), Chiba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8728-5130","authenticated-orcid":false,"given":"Yasuhiko","family":"Ikari","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging Research, Kobe City Medical Center General Hospital, Kobe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8333-5378","authenticated-orcid":false,"given":"Yuki","family":"Hoda","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging Research, Kobe City Medical Center General Hospital, Kobe"},{"name":"Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1065-0088","authenticated-orcid":false,"given":"Keiji","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging Research, Kobe City Medical Center General Hospital, Kobe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging Research, Kobe City Medical Center General Hospital, Kobe"},{"name":"Department of Biomedical Information Sciences, Hiroshima City University, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Senda","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging Research, Kobe City Medical Center General Hospital, Kobe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3372-6046","authenticated-orcid":false,"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, LMU Hospital, and German Cancer Consortium (DKTK), partner site Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6302-1966","authenticated-orcid":false,"given":"Naoko","family":"Nose","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6165-1689","authenticated-orcid":false,"given":"Xinyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9711-7835","authenticated-orcid":false,"given":"Takahiro","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan"},{"name":"Department of Nuclear Medicine and Comprehensive Heart Failure Center (DZHI), University Hospital of Wu\u0308rzburg, Wu\u0308rzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"R1-20260605","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/eurheartj\/ehae885","article-title":"Incident heart failure and recurrent coronary events following acute myocardial infarction","volume":"46","author":"Butler","year":"2025","journal-title":"Eur Heart J"},{"key":"R2-20260605","doi-asserted-by":"crossref","first-page":"e038644","DOI":"10.1161\/JAHA.124.038644","article-title":"Heart disease mortality in the United States, 1970 to 2022","volume":"14","author":"King","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"R3-20260605","doi-asserted-by":"crossref","first-page":"960606","DOI":"10.3389\/fnsyn.2022.960606","article-title":"The plasticity of cardiac sympathetic nerves and its clinical implication in cardiovascular disease","volume":"14","author":"Kanazawa","year":"2022","journal-title":"Front Synaptic Neurosci"},{"key":"R4-20260605","doi-asserted-by":"crossref","first-page":"e012549","DOI":"10.1161\/CIRCIMAGING.121.012549","article-title":"Positron emission tomography imaging of regional versus global myocardial sympathetic activity to improve risk stratification in patients with ischemic cardiomyopathy","volume":"14","author":"Zelt","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"R5-20260605","doi-asserted-by":"crossref","first-page":"6","DOI":"10.17996\/anc.23-00008","article-title":"Cardiac sympathetic nerve function in patients with severe aortic stenosis prior and after transcatheter aortic valve implantation: Evaluation by 5-year risk model","volume":"10","author":"Egi","year":"2024","journal-title":"Ann Nucl Cardiol"},{"key":"R6-20260605","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2967\/jnumed.115.156406","article-title":"123I-MIBG imaging for prediction of mortality and potentially fatal events in heart failure: the ADMIRE-HFX study","volume":"56","author":"Narula","year":"2015","journal-title":"J Nucl Med"},{"key":"R7-20260605","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11886-025-02197-9","article-title":"Novel F-18-labeled tracers of sympathetic function for improved risk stratification and clinical outcomes","volume":"27","author":"Zohora","year":"2025","journal-title":"Curr Cardiol Rep"},{"key":"R8-20260605","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00702-020-02180-4","article-title":"Recent advances in radiotracers targeting norepinephrine transporter: structural development and radiolabeling improvements","volume":"127","author":"Chen","year":"2020","journal-title":"J Neural Transm (Vienna)"},{"key":"R9-20260605","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.7150\/thno.96743","article-title":"Navigating new horizons: prospects of NET-targeted radiopharmaceuticals in precision medicine","volume":"14","author":"Higuchi","year":"2024","journal-title":"Theranostics"},{"key":"R10-20260605","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/MOU.0000000000001040","article-title":"Adrenal functional imaging - which marker for which indication?","volume":"32","author":"Werner","year":"2022","journal-title":"Curr Opin Urol"},{"key":"R11-20260605","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Taieb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20260605","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00259-010-1491-4","article-title":"Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology","volume":"37","author":"Flotats","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20260605","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1007\/s00259-019-04629-5","article-title":"Reliable quantification of myocardial sympathetic innervation and regional denervation using [11C]meta-hydroxyephedrine PET","volume":"47","author":"Wu","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R14-20260605","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2967\/jnumed.117.193169","article-title":"Biodistribution and dosimetry of 18F-meta-fluorobenzylguanidine: a first-in-human PET\/CT imaging study of patients with neuroendocrine malignancies","volume":"59","author":"Pandit-Taskar","year":"2018","journal-title":"J Nucl Med"},{"key":"R15-20260605","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2967\/jnumed.114.140137","article-title":"Biodistribution and radiation dosimetry of LMI1195: first-in-human study of a novel 18F-labeled tracer for imaging myocardial innervation","volume":"55","author":"Sinusas","year":"2014","journal-title":"J Nucl Med"},{"key":"R16-20260605","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s11307-019-01407-5","article-title":"Initial evaluation of AF78: a rationally designed fluorine-18-labelled PET radiotracer targeting norepinephrine transporter","volume":"22","author":"Chen","year":"2020","journal-title":"Mol Imaging Biol"},{"key":"R17-20260605","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.7150\/thno.63205","article-title":"Molecular imaging-derived biomarker of cardiac nerve integrity\u2014introducing high NET affinity PET probe 18F-AF78","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"R18-20260605","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3390\/pharmaceutics15020690","article-title":"Rationalizing the binding modes of PET radiotracers targeting the norepinephrine transporter","volume":"15","author":"Tutov","year":"2023","journal-title":"Pharmaceutics"},{"key":"R19-20260605","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2967\/jnumed.117.196261","article-title":"RADAR dose estimate report: a compendium of radiopharmaceutical dose estimates based on OLINDA\/EXM version 2.0","volume":"59","author":"Stabin","year":"2018","journal-title":"J Nucl Med"},{"key":"R20-20260605","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2967\/jnumed.108.056036","article-title":"MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature","volume":"50","author":"Bolch","year":"2009","journal-title":"J Nucl Med"},{"key":"R22-20260605","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/HP.0000000000001682","article-title":"OLINDA\/EXM 2-the next-generation personal computer software for internal dose assessment in nuclear medicine","volume":"124","author":"Stabin","year":"2023","journal-title":"Health Phys"},{"key":"R23-20260605","doi-asserted-by":"crossref","first-page":"7111","DOI":"10.7150\/thno.102552","article-title":"Molecular imaging along the heart-kidney axis","volume":"14","author":"Klimek","year":"2024","journal-title":"Theranostics"},{"key":"R24-20260605","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00259-022-05941-3","article-title":"123I-MIBG imaging in heart failure: impact of comorbidities on cardiac sympathetic innervation","volume":"50","author":"Gargiulo","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R25-20260605","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2967\/jnumed.115.158493","article-title":"Retention kinetics of the 18F-labeled sympathetic nerve PET tracer LMI1195: comparison with 11C-hydroxyephedrine and 123I-MIBG","volume":"56","author":"Werner","year":"2015","journal-title":"J Nucl Med"},{"key":"R26-20260605","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1152\/physrev.00014.2017","article-title":"Impact of the autonomic nervous system on the skeleton","volume":"98","author":"Elefteriou","year":"2018","journal-title":"Physiol Rev"},{"key":"R27-20260605","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.2967\/jnumed.110.077933","article-title":"Molecular mechanisms of bone 18F-NaF deposition","volume":"51","author":"Czernin","year":"2010","journal-title":"J Nucl Med"},{"key":"R28-20260605","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1071-3581(97)90010-6","article-title":"Comparison of [123I]metaiodobenzylguanidine kinetics with heart rate variability and plasma norepinephrine level","volume":"4","author":"Kurata","year":"1997","journal-title":"J Nucl Cardiol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:00:11Z","timestamp":1780689611000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006504"}},"subtitle":["Biodistribution, Dosimetry, and Safety"],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006504","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"2025-12-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}